Business context and reporting period
The filing is Fluidigm Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2020. The filing names Fluidigm Corporation as the registrant; the request metadata identifies Standard BioTools Inc. Fluidigm develops and sells life-sciences research instruments, consumables, and services, including mass cytometry and microfluidics products.
Key financial metrics
| Metric | Q1 2020 | Q1 2019 or comparison |
|---|---|---|
| Revenue | $27.6 million | $30.1 million; down 8% |
| Product revenue | $19.0 million | $24.8 million; down 24% |
| Service revenue | $5.2 million | $5.3 million; down 2% |
| Operating loss | $14.9 million | $14.2 million |
| Net loss | $16.0 million; $0.23 per share | $25.5 million; $0.44 per share |
| Product and service gross margin | 53.8% | 56.4%; down 2.6 percentage points |
| Cash used in operating activities | $4.3 million | $20.1 million |
At March 31, 2020, cash and cash equivalents were $35.0 million and short-term investments were $13.5 million; restricted cash was $1.1 million. The company reported $8.6 million available under its revolving credit facility and no facility borrowings. Convertible notes had $56.1 million aggregate principal and a $53.9 million net carrying value. Operating lease liabilities totaled $40.8 million. Working capital, excluding deferred revenue and restricted cash, was $59.7 million.
Material changes versus the prior period
- Revenue fell primarily as COVID-19-related closures and restrictions reduced customer activity, instrument purchases, and consumables demand. Product declines were partly offset by $3.1 million of license revenue and $0.4 million of grant revenue, neither reported in Q1 2019.
- Asia-Pacific revenue decreased 48% to $4.7 million; Americas revenue increased 14% to $14.8 million, including the license and grant revenue; EMEA revenue was approximately flat at $8.1 million.
- Net loss narrowed year over year, mainly because Q1 2019 included a $9.0 million debt-extinguishment loss and higher interest expense. Operating loss, by contrast, widened.
- Cash used in operations improved year over year. Investing cash flow was positive $17.5 million, mainly reflecting $23.6 million of investment maturities, partly offset by $5.2 million paid net for the InstruNor acquisition.
- The January acquisition of InstruNor cost approximately $7.2 million, paid with $5.2 million cash and 485,451 shares, and added developed technology and goodwill.
Outlook, risks, contingencies, and unusual items
- Management said COVID-19 had materially slowed customer activity, particularly at academic and medical research laboratories, and that near-term research priorities were shifting. The duration and financial impact remained uncertain.
- The company began expense and liquidity measures, including salary reductions and constrained hiring. It expected existing cash, cash equivalents, and investments to cover working capital and capital spending needs for at least 18 months, while warning that weaker cash generation or higher costs could require additional capital.
- No specific revenue or earnings guidance was provided. Management expected continued investment in research and development and noted possible deferral of capital expenditures and development activities.
- A COVID-19-triggered impairment review found no impairment of goodwill or developed technology in the quarter. Goodwill and developed technology were approximately $106.3 million and $48.6 million, respectively.
- On April 21, 2020, after quarter-end, the company extended its revolving facility maturity to August 2, 2022 and reduced its minimum interest rate to 5.25%.
- A March intellectual-property settlement generated a $3.5 million payment: $3.1 million was recognized as license revenue and $0.4 million offset legal costs. The filing states pending legal matters were not expected to have a material adverse effect, while noting litigation outcomes are uncertain.
- Management identified COVID-19, ongoing losses, competition, customer research-budget constraints, supply concentration, foreign-exchange exposure, and potential financing needs as significant risks. Disclosure controls were assessed as effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer identity and whether this Fluidigm filing is the intended filing for the company identified in the request metadata.
- Track the effects of COVID-19 on instrument orders, consumables pull-through, customer laboratory access, and subsequent-quarter revenue.
- Assess operating cash burn and liquidity against management’s 18-month sufficiency statement, including any further cost reductions or financing needs.
- Review convertible-note terms, including the 2021 holder repurchase right on the remaining 2014 Notes and potential dilution from the 2019 Notes.
- Monitor InstruNor integration, the expected benefits of the acquisition, and future impairment assessments.
- Separate recurring product and service performance from the quarter’s one-time license settlement and investment-maturity cash inflows.